In the patient-derived xenografts, HCC using humanized mice or syngeneic HCC models, TTI-101 treatment enhances the anti-tumor effect of anti-PD-1 ICI therapy, further supporting the role of TTI-101 in modulating the TME [79]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.